Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. First BEAT (Bevacizumab Expanded Access Trial).

Next Previous
X
Search
Trial Profile

First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. First BEAT (Bevacizumab Expanded Access Trial).

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Antineoplastics; Capecitabine; Fluorouracil; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions; Expanded access
  • Acronyms BEAT; First-BEAT
  • Sponsors Roche

    • Most Recent Events

    • 02 Aug 2011 New source identified and integrated (European Clinical Trials Database).
    • 23 Sep 2009 Results were presented at the Joint 15th European Cancer Conference (ECCO) and the 34th Congress of the European Society for Medical Oncology (ESMO), held in Berlin, Germany.
    • 12 Sep 2008 Results for the final overall survival analysis reported at ESMO 2008.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top